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ABSTRACT
The proportion of methicillin-resistant Staphylococcus aureus (MRSA) in Denmark has been below 1% for
more than 30 years. However, a marked increase in community-onset MRSA (CO-MRSA) started in
2002. To identify possible risk factors for CO-MRSA infections, a nationwide case–control study was
conducted in 2004. Cases (34) were patients with CO-MRSA infections; controls (87) were patients with
community-onset methicillin-sensitive S. aureus infections (CO-MSSA). Demographic and clinical data
and exposures to possible risk factors during the last 24 months were collected with a structured
telephone-administered questionnaire. Skin and soft tissue were the predominant sites of infection, both
for cases (68%) and for controls (60%). A large proportion of cases (26%) and controls (38%) had an
underlying skin disease. The majority of cases (76%) and controls (61%) had received antibiotics within
the last 6 months, and 51% and 31%, respectively, had been hospitalized within the previous year. In a
multivariate analysis, non-Danish origin, deﬁned as being from or having parents from outside
Denmark, was the only independent risk factor for CO-MRSA infection (OR 30.5, 95% CI 3.6–257.3).
Prior hospitalization for >7 days within the previous 6 months tended to be associated with CO-MRSA
infection (OR 5.7, 95% CI 0.9–36.4). The predominant MRSA clones found in this study were CC80
(26%), CC8 (24%) and CC5 (18%). Resistance to three or more antimicrobial drug classes was seen in
47% of CO-MRSA isolates. Panton–Valentine leukocidin was found in 47% of CO-MRSA isolates. Apart
from a non-Danish origin, CO-MRSA shared the same risk factors as CO-MSSA, which makes control a
challenge.
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INTRODUCTION
The burden of infections due to methicillin-resis-
tant Staphylococcus aureus (MRSA) continues to
increase worldwide [1,2]. This can be ascribed
partly to a recent change in the epidemiology of
MRSA infections; MRSA is no longer conﬁned to
the healthcare environment, but is increasingly
seen in outpatients [3,4]. The change in epidemi-
ology has been concomitant with a change in the
characteristics of the circulating MRSA strains
[5,6]. Strains responsible for community-onset
infections (CO-MRSA) often contain the smaller
staphylococcal cassette chromosome mec
(SCCmec) elements IV and V, which seem to be
introduced more easily into methicillin-suscepti-
ble strains and entail a lower cost of ﬁtness for the
bacteria [7]. This has led to the emergence of new
MRSA strains, which are now spreading in the
community.
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For more than 30 years, Denmark has had a
low prevalence (<1%) of MRSA (http://www.
ssi.dk/sw3425.asp). This has been achieved by a
rigorous practice of isolation of all hospitalized
patients suspected or conﬁrmed to be MRSA-
positive, and a relatively low antibiotic selection
pressure due to a restricted use of broad-spec-
trum antimicrobials. However, the low preva-
lence of MRSA probably also reﬂects the fact that
MRSA has, until recently, been conﬁned to the
healthcare sector. The number of MRSA cases in
Denmark has increased by a factor of 10 during
the last decade, primarily due to emerging clones
responsible for CO-MRSA infections (http://
www.ssi.dk/sw45633.asp).
Cases of MRSA detected outside the hospital
setting consist of two groups: (i) patients with
community onset and healthcare-related risk fac-
tors (Healthcare Associated Community Onset
[HACO]), e.g. previous hospitalization, residence
in a nursing home or employment in a health care
setting; and (ii) patients without healthcare-
related risk factors, but rather community risk
factors, e.g. sports activity, day-care institution, or
prison residence, and those with no known risk
factor (Community Associated [CA]).
Several risk factors have been reported for CA
infections, including poor hygiene combined with
a crowded environment [8–12]. Most of these
studies have been carried out in countries with a
high prevalence of MRSA, and often in highly
selected populations such as prison inmates and
military personnel [9,13]. Little is known about
the risk factors for MRSA in the general popula-
tion in low-prevalence countries such as Den-
mark. However, two recent Danish studies have
described CO-MRSA related to local outbreaks,
and found kindergarden attendance, nursing
home residence, previous hospitalization and
travel abroad to be important risk factors for
acquisition and spread of MRSA [14,15].
The objective of the present study was to
identify the risk factors for MRSA infection
among persons infected with S. aureus in the
Danish community. Identiﬁcation of such risk
factors would facilitate the development of guide-
lines to identify, at the time of consultation with a
general practitioner or upon hospital admission,
which type of patient with suspected S. aureus
infection would be more likely to require empir-
ical treatment covering MRSA and which mea-
sures would prevent further transmission.
METHODS
A prospective case–control study was conducted from January
to December 2004.
A case of CO-MRSA was deﬁned as a patient infected with
MRSA and seeking outpatient care, i.e. from a general
practitioner or at a hospital emergency room. A control was
deﬁned as patient with a community-onset methicillin-sensi-
tive S. aureus (MSSA) infection (CO-MSSA), seeking outpatient
care.
The local clinical microbiology laboratories identiﬁed eligi-
ble MRSA cases and MSSA controls. MSSA controls were
randomly selected among persons with CO-MSSA identiﬁed
on the same day as the case from ﬁve of the participating
laboratories.
Following written consent, patients were interviewed using
a structured, telephone-administered questionnaire that cap-
tured demographic and clinical data, i.e. socio-economic
status, household composition, non-Danish origin (deﬁned as
being from or having parents with a country of origin other
than Denmark), and exposure to possible risk factors during
the last 24 months. The questionnaire also included informa-
tion about hospitalization, emergency room visits or outpatient
visits to clinics, surgical procedures, underlying medical
conditions, antibiotic use, intravenous drug use, dermato-
logical conditions, household contact with MRSA-infected
persons, household contact with persons with known risk
factors for MRSA, occupation as a healthcare worker in a
hospital or a long-term care facility, close contact with a
healthcare worker, close contact with nursing home residents,
foreign travel, and day-care attendance.
Patients who, for physical or mental reasons, could not
participate in the interview were excluded from the study.
For each case and each control, the general practitioner in
charge of the patient was contacted by mail. They were
informed about the study and asked to provide information on
the clinical picture of the patient’s S. aureus infection, as well as
on relevant comorbidity factors. A standard questionnaire and
a pre-stamped return envelope were provided.
MRSA and MSSA isolates were identiﬁed using the stan-
dard methods of the local laboratory. All MRSA isolates were
sent to Statens Serum Institut for conﬁrmation and further
characterization, including creation of an antimicrobial sus-
ceptibility proﬁle. The MRSA isolates were typed by pulsed-
ﬁeld gel electrophoresis (PFGE) according to the HARMONY
protocol [16]. Restriction patterns were analyzed with
BIONUMERICS version 4.61 (Applied Maths, St. Martenlatem,
Belgium) using Dice coefﬁcients and the unweighted pair
group method with arithmetic mean (UPGMA). A similarity
coefﬁcient of ‡80% was used to deﬁne major clusters or PFGE
types [17]. The PFGE types were annotated to clonal com-
plexes (CCs), on the basis of sequence typing of spa [18] and ⁄ or
multilocus sequence typing [19] of representatives from each
PFGE cluster. The presence of the lukF ⁄ lukS gene for produc-
tion of Panton–Valentine leukocidin (PVL) was determined as
previously described [20].
Susceptibility testing of the MRSA isolates was performed
using Neo-Sensitabs (Rosco, Taastrup, Denmark) on Danish
Blood agar (Statens Serum Institut, Copenhagen, Denmark)
with semiconﬂuent (106 CFU ⁄mL) inoculum and overnight
incubation in ambient air at 35–36C. Susceptibility to glyco-
peptides was tested using the Etest (AB BIODISK, Solna,
Sweden) macromethod for screening and Population Analysis
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Proﬁle-Area Under the Curve (PAP-AUC) as conﬁrmation
[21,22]. Antimicrobial multiresistance was deﬁned as resis-
tance against three or more different classes of antimicrobial
drugs (other than methicillin).
Statistical analysis was performed using STATA STATISTICAL
SOFTWARE 8 (Stata Corporation, College Station, TX, USA).
Univariate analysis was performed with a Pearson chi-squared
test for the different exposures. For the multivariate analysis, a
backward stepwise logistic regression model for variables with
p <0.25 was built.
The Danish Scientiﬁc Ethical Committee approved the
study protocol and all relevant documents used during the
study.
RESULTS
Between January and December 2004, 13 partici-
pating clinical microbiology laboratories in Den-
mark identiﬁed 99 eligible MRSA patients and 330
eligible MSSA patients. Fifteen MRSA and 14
MSSA patients did not meet the inclusion criteria.
Among the eligible patients meeting the inclusion
criteria, 46 MRSA patients and 87 MSSA patients
agreed to participate in the study and were
interviewed. For 34 MRSA patients and 87 MSSA
patients, additional clinical information was re-
ceived from their respective general practitioners.
Analyses were performed on these 121 patients (34
cases and 87 controls). The average delay between
diagnosis of infection and interview was 140 days
for the cases and 205 days for the controls.
No signiﬁcant differences in the male ⁄ female
ratio or age ranges were found (Table 1). Most
people in both groups attended school for 9–
11 years, and the three most populated categories
reﬂecting current occupation in both groups were
retired people, schoolchildren and skilled work-
men. Approximately 25% of the cases had a
country of origin other than Denmark, whereas
only one control had such a background (Table 1).
In both groups, a high proportion of patients
had been hospitalized within the last 2 years
(cases 52%, controls 66%) and a high percentage
had received antibiotics within the last 2 years
(cases 76%, controls 69%). Within the last
12 months, 66% of cases and 49% of controls
had received antibiotics. The use of steroids was
high in both groups (cases 24%, controls 37%),
and included both topical steroids for skin dis-
eases and systemic or inhalation steroids for
pulmonary diseases.
In the univariate analysis, two risk factors were
found to be signiﬁcant (p <0.05): previous hospi-
talization for more than 7 days within 6 months
before infection (p 0.03) and non-Danish origin
(deﬁned as being from or having parents with a
country of origin other than Denmark) (p <0.001)
(Table 2).
In the multivariate analysis, the only signiﬁcant
risk factor for CO-MRSA infection was non-
Danish origin (Table 3). In addition, prior hospi-
talization for more than 7 days within the last
6 months tended to be associated with CO-MRSA
infection. None of the cases or the controls
reported using intravenous drugs.
The predominant type of infection was skin and
soft tissue infection, among both cases (68%)
and controls (60%). The sites of infection were
Table 1. Demographic characteristics of methicillin-resis-
tant Staphylococcus aureus (MRSA) cases and methicillin-
susceptible S. aureus (MSSA) controls
Characteristic MRSA (n = 34) MSSA (n = 87)
Sex (male ⁄ female ratio) 1.0 0.7
Median age, years (range) 38 (1–88) 43 (0–83)
Country of origin (n) Denmark (26)
USA (2)
Jordan (2)
Spain (1)
Switzerland (1)
Finland (1)
Iran (1)
Denmark (86)
Swedish (1, one parent)
Table 2. Univariate analysis of risk factors ⁄ exposures for
community-onset methicillin-resistant Staphylococcus aur-
eus (MRSA) infections in Denmark
Risk factor
No. of
MRSA (%)
n = 34
No. of
MSSA (%)
n = 87 OR (95% CI) p-Value
Contact with day care 6 (18) 18 (21) 0.92 (0.29–2.84) 0.87
Contact with healthcare 9 (26) 19 (21) 1.29 (0.45–3.51) 0.59
Steroids 8 (24) 32 (37) 0.57 (0.20–1.53) 0.22
Underlying skin disease 9 (26) 33 (38) 0.58 (0.22–1.50) 0.22
Prior antibioticsa 26 (76) 60 (69) 1.8 (0.6–6.2) 0.21
Sports 20 (59) 40 (46) 1.68 (0.70–4.05) 0.20
Travel abroad 25 (73) 49 (56) 2.15 (0.84–5.84) 0.08
Prior hospitalizationb 4 (12) 2 (2) 5.67 (0.75–64.52) 0.03
Non-Danish originc 8 (24) 1 (1) 27.52 (3.21–615.11) <0.001
MSSA, methicillin-susceptible S. aureus.
aFor 2 years before MRSA infection.
bFor more than 7 days, within 6 months before MRSA infection.
cIncluding one MRSA case and one MSSA control from other low-incidence
countries.
Table 3. Multivariate analysis of independent risk factors
for community-onset methicillin-resistant Staphylococcus
aureus (MRSA) infections in Denmark
Risk factor OR 95% CI p-Value
Non-Danish origina 30.5 3.6–257.3 0.002
Prior hospitalizationb 5.7 0.9–36.4 0.064
aOR increases to inﬁnity if persons from low-endemicity countries are excluded.
bFor more than 7 days, within 6 months before MRSA infection.
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primarily the face, the legs and the hands. Approx-
imately one-third of the participants had an under-
lying skin disease. Besides skin and soft tissue
infections, only urinary tract infections, ear infec-
tions and sinusitis were observed. None of the
participants had an invasive infection. Chronic
obstructive lung disease and diabetes were the
most prevalentunderlyingdiseases in bothgroups.
Microbiological investigation (Table 4) showed
that 68% of the isolates belonged to one of the
three following types: CC80 (26%), CC8 (24%)
and CC5 (18%). Four of the eight CC8 isolates
belonged to the USA 500 clone. Twenty-eight
(82%) of the 34 isolates carried SSCmecIV, two
CC398 isolates carried SSCmecV, and four isolates
were non-typeable. In total, 47% of MRSA isolates
were PVL-positive. All CC80 and CC30 iso-
lates were PVL-positive. CC8 was the predomi-
nant clone among patients with a history of
hospitalization, whereas CC80 was the predomi-
nant clone among patients with no obvious risk
factor or a history of acquisition in the commu-
nity, e.g. within the household.
Among the 34 MRSA isolates, 47% were resis-
tant to three or more antibiotic classes. All isolates
were susceptible to rifampicin and linezolid.
Eighty-ﬁve percent were susceptible to cipro-
ﬂoxacin, 68% to clindamycin, 65% to fusidic acid,
and 62% to erythromycin. Glycopeptide resis-
tance was tested for 30 of the 34 MRSA isolates,
and all were susceptible.
DISCUSSION
In the present study, the aim was to identify risk
factors for MRSA infections with community
onset. By choosing CO-MSSA patients as the
control group, risk factors for CO-MRSA among
patients with staphylococcal infections were
investigated. This choice of design was motivated
by the objective of identifying risk factors speciﬁc
to MRSA in the community, in order to enable
general practitioners or hospital physicians to
decide upon empirical treatment for MRSA in
patients with signs and symptoms compatible
with staphylococcal infections.
The study was based on a representative
sample of patients with staphylococcal infection
from the general population in Denmark. To our
knowledge, this is the ﬁrst national study com-
paring risk factors for CO-MRSA and CO-MSSA
infection in a low-prevalence country.
Demographic and clinical differences and var-
ious exposures were sought. The only signiﬁcant
risk factor for CO-MRSA infections in Denmark
was non-Danish origin. An increased frequency
of close contact with relatives and friends still
living in countries where MRSA is highly pre-
valent is a probable explanation for this ﬁnding.
In several studies, lower socio-economic status
was found to be a risk factor for CO-MRSA
infection [12,20,23], but no differences related to
educational background and socio-economic sta-
tus were observed in this study.
Two cases were presumably related to pig
farming; one individual worked at a pig farm and
the other had a farm in the same area in Denmark.
Both were infected with type CC398, which in The
Netherlands has been related to pig farming and
to veterinarians in contact with pig farms [24,25].
MRSA type CC398 has now been reported from
pig farms in Denmark [26]. In The Netherlands,
this clone is now responsible for a number of
MRSA infections, which, in most cases, have a
community onset [25]. In this case–control study,
we did not systematically collect data on animal
exposure, which, retrospectively, is seen as an
increasingly important risk factor.
The present study highlighted some general
characteristics of patients with staphylococcal
infections, although it was not possible to quan-
tify these characteristics, as an appropriate group
of community controls without staphylococcal
infections was not included. In both cases and
controls, a high prevalence of underlying disease,
i.e. skin disease, diabetes and chronic lung dis-
ease, was noted. An underlying skin disease was
reported by 26% of cases and 38% of controls, as
Table 4. Expression of SSCmec types, Panton–Valentine
leukocidin (PVL) and multiresistance in the 34 isolates
from methicillin-resistant Staphylococcus aureus (MRSA)
cases
CC
group
No. of
isolates
SSCmec type
(no. of isolates)
No. of
PVL-positive
isolates
No. of
multiresistant
isolatesa
CC80 9 IV (9) 9 7
CC8 8 IV (6), NT (2) 3 5
CC5 6 IV (5), NT (1) 1 1
CC30 3 IV (3) 3 0
CC398 2 V 0 2
CC1 1 IVA 0 0
CC22 1 IV 0 0
CC45 1 NT 0 0
CC59 1 IV 0 0
CC72 1 IV 0 1
CC97 1 IV 0 0
CC, clonal complex; NT, non-typeable.
aResistant to three or more antimicrobial drugs other than methicillin.
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compared to an estimated prevalence of skin
disease in 7–10% of the general population. This
corresponds to what has been reported in previ-
ous studies regarding skin disease and carriage
rate for staphylococci [27–29]. Use of antibiotics
during the previous 6 months was high, among
both cases (66%) and controls (49%). In compar-
ison, the percentage of individuals in Denmark
who receive an antibiotic each year is c. 30%
(http://www.dkma.dk). The use of steroids was
also high in both groups, and is probably higher
than in the general population, due to the high
prevalence of skin disease and chronic lung
disease in these patients. Both groups had a high
rate of prior hospitalization, and hospitalization
of more than 7 days within the last 6 months
tended to be a risk factor for MRSA infection.
This, however, could be a coincidental observa-
tion, as the MRSA clones isolated from these
patients were not classical hospital clones, but
rather clones that are seen in both the community
and hospitals, i.e. CC5, CC8 and CC59.
The present study has some limitations. The
number of cases was small, which reduces the
study’s statistical power and prevented the use of
matching criteria, e.g. age, which would have
been relevant, as risk factors for MRSA infection
vary between children and the elderly. The
ﬁndings should therefore be interpreted with
caution. On the other hand, the cases and controls
were consecutively chosen from 13 of the 15
departments of clinical microbiology in Denmark,
and can therefore be considered to be represen-
tative of the country. This is corroborated by the
clonal distribution, which corresponds to national
surveillance data concerning all MRSA cases in
Denmark that were categorized as community
onset in 2004 (CC80 25%, CC8 23%, CC5 17%).
Bias in relation to socio-economic status
might have occurred, even though the cases
and controls were randomly selected at the local
departments of clinical microbiology. Only
c. 46% of cases agreed to participate, and this
could have introduced selection bias. In addi-
tion, selection bias might also have occurred for
non-Danish cases and controls, as non-Danish
individuals may have had difﬁculties in under-
standing and answering the questionnaire.
Finally, the long delay from diagnosis to inter-
view may have introduced recall bias, and thus
detailed information concerning antibiotics used
prior to the MRSA ⁄MSSA infection was not
used, as many patients did not recall the name,
the dose or the exact reason for antibiotic
prescription.
The increasing number of MRSA cases within a
healthy population without obvious risk factors is
worrisome. In Denmark, antistaphylococcal pen-
icillins, e.g. dicloxacillin, are the drugs of choice
for the treatment of suspected staphylococcal
infections. For outpatients, treatment is often
initiated without taking a clinical sample. In the
case of MRSA infections, this would lead to
delayed initiation of adequate therapy, with a
risk of a poorer outcome. Furthermore, delayed
initiation of adequate therapy increases the period
during which transmission is possible, which
contributes not only to the increase of MRSA in
the community, but also to repeated introduction
of community MRSA into hospitals, with the risk
of causing serious nosocomial infections. Never-
theless, and considering the present low preva-
lence of MRSA in Denmark, changing the national
recommendation for suspected staphylococcal
infections from an antistaphylococcal penicillin
to a drug including MRSA in its spectrum of
activity, e.g. linezolid, would be a threat to the
Danish antibiotic policy, which gives preference
to penicillins and, in general, narrow-spectrum
antibiotics. It would also result in increasing costs
for the healthcare system and possibly increase
the number of patients with adverse side effects
from these drugs.
Denmark remains a low-prevalence country
despite the alarming increase in the number of
MRSA cases, especially with community onset.
This study was designed with the purpose of
identifying risk factors for MRSA infection in a
low-prevalence country, in order to allow devel-
opment of a prediction rule to identify which
patients require empirical treatment for MRSA at
the time of consulting a general practitioner or at
hospital admission. On the basis of the ﬁndings in
this study, we advise physicians to be aware that
among patients with a presumed staphylococcal
infection, those patients with social contacts, i.e.
relatives and possibly close friends, in countries
with a high prevalence of MRSA, as well as
patients who have frequently been hospitalized
for longer periods, should be considered at risk
for MRSA. The study further indicates that many
of the risk factors for CO-MRSA infection are also
risk factors for staphylococcal infections in gen-
eral. Because MRSA shares these characteristics
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with MSSA, it is at present impossible to establish
a clinical epidemiological algorithm that would
give precise decision support for the management
of staphylococcal infections besides the two
aforementioned risk factors. This makes control
of CO-MRSA a particular challenge.
In November 2006, the Danish National Board
of Health made MRSA a reportable disease and
launched national MRSA control guidelines
(http://www.sst.dk/publ/Publ2006/CFF/MRSA/
Vejl_MRSA.pdf). These guidelines include recom-
mendations regarding hygienic precautions, as
well as household cleaning and disinfection, for
MRSA patients identiﬁed at outpatient clinics or
by a general practitioner.
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